Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $120.00 Price Target at Wells Fargo & Company

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lowered by Wells Fargo & Company from $140.00 to $120.00 in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the specialty pharmaceutical company’s stock.

Several other research firms have also recently weighed in on JAZZ. StockNews.com cut shares of Jazz Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Friday, July 5th. Cantor Fitzgerald restated an overweight rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an overweight rating on the stock in a research report on Friday, May 3rd. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an outperform rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a buy rating and a $169.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $175.20.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded down $1.15 on Thursday, hitting $112.11. The stock had a trading volume of 352,530 shares, compared to its average volume of 684,108. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $146.70. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.90 and a current ratio of 2.37. The company has a market capitalization of $7.07 billion, a price-to-earnings ratio of 19.65, a price-to-earnings-growth ratio of 1.76 and a beta of 0.58. The firm has a 50-day moving average of $107.82 and a 200-day moving average of $114.05.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Rise Advisors LLC lifted its position in Jazz Pharmaceuticals by 2,255.6% during the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after acquiring an additional 203 shares during the period. Versant Capital Management Inc lifted its position in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after acquiring an additional 269 shares during the period. GAMMA Investing LLC raised its holdings in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the last quarter. Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals in the second quarter worth about $33,000. Finally, Cape Investment Advisory Inc. raised its holdings in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after buying an additional 292 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.